Monoclonal antibodyFDA-approvedSecond-line
Erbitux
Generic name: cetuximab
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, inhibiting tumor growth.
Cancer types
Colorectal Cancer— EGFR-expressing
Efficacy
In clinical trials, Erbitux in combination with chemotherapy improved median overall survival by approximately 4 months compared to chemotherapy alone in EGFR-expressing patients.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Combination Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing IBI351 with Cetuximab in Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Medicine for Advanced Solid Tumors with KRAS Mutations | Lung Cancer | phase-1 | — | Source → |
| Combining Treatments for Lung Cancer | Lung Cancer | lab-study | Response rates of 41% and 49% and median progression-free survival of 6.3 and 9.7 months. | Source → |
| New Treatment Option for Chinese Patients with Aggressive Colorectal Cancer | Colorectal Cancer | phase-2 | The Doublet arm demonstrated superior progression-free survival of 4.2 months vs. 2.5 months in the Control arm. | Source → |
| Succinate Helps Cancer Cells Resist Treatment | Colorectal Cancer | lab-study | — | Source → |
| Butyrate May Reduce Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Machine Learning Predicts Cancer Treatment Outcomes | Colorectal Cancer | phase-3 | Higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations (p = .003). | Source → |
| RAS Mutations in Blood Linked to Poorer Outcomes in Colorectal Cancer | Colorectal Cancer | phase-2 | The presence of ctDNA RAS mutations at any time point was significantly associated with poorer progression-free survival (adjusted HR = 2.24, P = .02). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.